News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Critical Therapeutics, Inc. (CRTX) Completes Phase II Clinical Trial for Zileuton Injection



6/3/2008 8:50:18 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced top-line results from its Phase II clinical trial of the injectable formulation of zileuton (zileuton injection), the Company’s investigational compound for acute asthma in the emergency department (ED). The clinical trial was designed to explore the pulmonary function profile, safety, tolerability and pharmacokinetic profile of zileuton injection.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES